舒血宁注射液联合复方异丙托溴铵雾化吸入治疗慢性阻塞性肺疾病急性加重期的临床研究

目的:研究并观察舒血宁注射液(shuxuening injection,SI)静脉滴注联合复方异丙托溴铵溶液(combivent)雾化吸入治疗慢性阻塞肺疾病急性加重期(AECOPD)的临床疗效。方法:抽取80例临床肯定诊断的AECOPD患者,随机分为两组:对照组(39例)给予常规治疗;观察组(41例)在对照组常规治疗的基础上,加用SI 15ml静脉滴注2次/d,10～14d为1个疗程,并同时给予combivent雾化治疗。疗程结束后检测和计算下列指标:C反应蛋白(CRP)、血细胞总数(Wbc)、纤维蛋白原(FIB)、血氧饱和度(SaO2)、动脉氧分压(PaO2)、动脉二氧化碳分压(PaCO2)、用力肺活量(Forced vital capcity,FVC)、第1秒用力呼气容积(Forced expiratory volume in one second,FEV1),并计算第1秒用力呼气容积与用力肺活量的比值FEV1/FVC(%)]及FEV1占预计值的百分比。随后比较两组总有效率和显效率,进行统计学分析,并观察两组治疗药物的不良反应。结果:治疗后两组患者CRP、Wbc、FIB有明显差异(P<0.01、P<0.05、P<0.05);两组SaO2、PaO2、PaCO2及FEV1/EVC(%)、FEV1(%)治疗后均有改善,但观察组较对照组改善更明显(P均<0.05);总有效率观察组和对照组分别为97.56%和87.18%,无明显差异(P<0.05);显效率两组分别为63.41%和41.0%,有显著差异(P<0.01)。疗程中,两组均未见明显的药物不良反应。结论:SI静脉滴注及combi-rent雾化治疗AECOPD疗效满意,较常规治疗具有一定优势,且无明显药物不良反应,值得临床推荐和进一步研究。

Clinical Study on Therapeutic Effects of Patients with Acute Exacerbated Chronic Obstructive Pulmonary Disease Treated by Shuxuening Injection and Atrovent

Objective:To study and observe the clinical effects of patients with acute exacerbated chronic obstructive pulmonary disease(AECOPD)treated by Shuxuening injection(SI)and combivent.Methods:80 patients with AECOPD were divided into two groups randomly;the control group(39 cases)was treated with routine therapy;while 15ml SI was given to those in the observation group(41 cases)by intravenous dripping,twice for total 10~14 days and conbivent on the basis of routine therapy.After therapy,the indexes such as CRP,Wbc,FIB,SaO2,PaO2,PaCO2 and forced vital capacity(FVC),forced expiratory volume in one second(FEV1),FEV1/EVC(%),FEV1(%)were detected and calculated;and than total effective rate and significant effective rate in two groups were compared and statistically analysed.Results:After treatment,CRP,Wbc,FIB were to show obvious difference between the two groups(P<0.01,P<0.05,P<0.05);Changes of SaO2,PaO2,PaCO2 and FEV1/FVC(%),FEV1were improved in two groups,but the improvement of the observation group were better than those of the control group(P<0.05 in all);the total effective rate in the observation group and the control group were 97.56% and 87.18% respectively(P>0.05),but the significant rate in the observation group and the control group were 63.41% and 41.03% respectively,showing were obviously difference between the two groups(P<0.01).In treatment,no obvious adverse effects were found in both two groups.Conclusion:The clinical effects of treatment in patients with AECOPD treated by SI intravenous dripping and combivent were pleased without obvious adverse effects,its effects were better than those of the contral group and it was worth recommendations and clinical application.